Recurrent Aphthous Stomatitis with Multiple Monthly Episodes and Difficulty Eating — When Topical Therapy Is Not Enough

Patients who continue to experience multiple aphthous ulcer episodes each month despite topical treatment, or who suffer severe oral pain that impairs eating, require a structured next-line approach beyond local measures.

This protocol addresses recurrent aphthous stomatitis (RAS) with multiple episodes each month, and/or severe oral pain with difficulty in eating — presentations where the frequency and functional impact of ulceration signal the need to move beyond topical-only management.
Previous line did not achieve goals

First-line topical agents — including protective pastes and gels, topical anesthetics, antibiotic mouthwashes, and topical glucocorticoids — were applied but failed to adequately decrease symptoms, reduce ulcer number and size, or increase disease-free periods. This protocol defines the evidence-based next step after that shortfall.

Next-line approach (partial overview)

Where topical management proves insufficient for severe, constantly recurring ulcerations, systemic immunomodulant and anti-inflammatory medications may be considered. The specific agents, selection criteria, and sequencing are detailed in the full structured regimen.

Treatment goals: Decrease symptoms; reduce ulcer number and size; increase disease-free periods.

References

  • Drug therapy is considered for patients who experience multiple episodes of RAS each month and/or present with symptoms of severe pain and difficulty in eating.
  • It is indicated for severe and constantly recurring ulcerations; the topical management is not effective in these cases.
  • Pakfetrat et al.,38 have conducted a double-blind randomized clinical trial to compare colchicine versus prednisolone (immunomodulant agents) in RAS and reported that low dose prednisolone and colchicine were both effective in treating RAS.
  • de Abreu et al.,39 reported that clofazimine should be considered for the treatment of RAS.
  • In severe cases of RAS, immunosuppressive, and anti-inflammatory drugs have shown varying degrees of success.
  • The aim of the treatment of RAS is to decrease symptoms; reduce ulcer number and size; increase disease-free periods.
View source ↗